Takeda's Rusfertide Approval Sets Up Biotech ETF Movement in Next 24 Hours

Takeda Pharmaceutical Company has recently received regulatory approval for its new drug, rusfertide, specifically indicated for the treatment of polycythemia vera. This rare blood disorder leads to an overproduction of red blood cells, increasing the risk of…